Moderna eyes producing vaccine in Asia after Japan rejected AstraZeneca – Nikkei
|Amid mixed vaccine developments, Moderna is considering manufacturing its covid vaccine in Japan while the country’s said it will not approve the AstraZeneca vaccine for the time being.
The government will continue monitoring blood clot cases overseas, as a side-effect of AstraZeneca’s covid vaccine.
Meanwhile, Moderna’s Chief Executive Stephane Bancel said in an interview with the Nikkei Asian Review, "We're having discussions in several countries in Asia, including Japan."
The Japanese government has made a contract with Moderna and is set to receive 50 million doses by September.
Bancel said the company is in discussions with Japan regarding additional supplies for next year. "If the government wants 50 million doses [for 2022] we can do that," he added.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.